Scynexis Inc (SCYX): Gonzalez David Angulo , Chief Medical Officer of Scynexis Inc purchased 36,950 shares on Jun 29, 2016. The Insider buying transaction was reported by the company on Jul 1, 2016 to the Securities and Exchange Commission. The shares were purchased at $2.20 per share for a total value of $82,158.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 28, 2016, Eric Francois (CFO) purchased 15,000 shares at $2.39 per share price.On Jun 28, 2016, Clarence Patrick Machado (director) purchased 20,000 shares at $2.39 per share price.Also, On Jun 28, 2016, Marco Taglietti (CEO) purchased 100,000 shares at $2.39 per share price.On Jun 28, 2016, Guy Macdonald (director) purchased 40,000 shares at $2.39 per share price.
SCYNEXIS Inc: On Wednesday, Jun 29, 2016 heightened volatility was witnessed in SCYNEXIS Inc which led to swings in the share price. The shares opened for trading at $2.23 and hit $2.27 on the upside , eventually ending the session at $2.26, with a gain of 1.80% or 0.04 points. The heightened volatility saw the trading volume jump to 2,07,473 shares. The 52-week high of the share price is $9.1 and the company has a market cap of $31 M . The 52-week low of the share price is at $2.05.
SCYNEXIS Inc. is a pharmaceutical company. The Company is engaged in the discovery development and commercialization of anti-infectives. It also provides contract research and development services primarily in the field of animal health. Its lead product candidate SCY-078 is an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. SCY-078 has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species including drug resistant strains. In addition the Company has additional compounds similar to SCY-078. The Company has developed a platform for cyclophilin inhibitors. Its cyclophilin inhibitor platform has two clinical stage compounds: SCY-635 which is a cyclophilin inhibitor for the treatment of dog dry eye and SCY-641 which is a cyclophilin inhibitor with activity similar to cyclosporine for the treatment of viral diseases in humans.